Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
Ann Rheum Dis
; 72(4): 583-9, 2013 Apr.
Article
em En
| MEDLINE
| ID: mdl-23144446
ABSTRACT
BACKGROUND:
Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.OBJECTIVE:
To review published evidence on safety and efficacy of IL-6i in inflammatory diseases.METHODS:
We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http//www.clinicaltrials.gov.RESULTS:
Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable.CONCLUSIONS:
IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite Juvenil
/
Artrite Reumatoide
/
Espondilite Anquilosante
/
Interleucina-6
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Clinical_trials
/
Guideline
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article